Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 2 RCTs; 192 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower immunoglobulins (Direct evidence; 2 RCTs; 192 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 2 RCTs; 190 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes immunoglobulins (Direct evidence; 2 RCTs; 190 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 2 RCTs; 91 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention probably leads to lower immunoglobulins (Direct evidence; 2 RCTs; 91 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 3 RCTs; 243 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes immunoglobulins (Direct evidence; 3 RCTs; 243 participants) (very low certainty).
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Polyvariant intramuscular immunoglobulin led to higher improvement in mucositis compared with placebo; GRADE not reported.
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in muscle mass at 12 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in grip strength · people with inclusion body myositis
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
Salivary immunoglobulin A and pH · children aged 6 to 12 years
No meta-analysis was conducted; postbiotic toothpaste was reported to increase salivary immunoglobulin A and pH versus fluoride toothpaste.
1 finding from 1 review
no estimate extracted
1 study
GRADE not reported
Salivary immunoglobulin A (SIgA) concentration · Children and adolescents (<18 years) living with HIV (CLWH)
Evidence on salivary IgA in CLWH on versus off ART was divergent and inconclusive (very low certainty).
1 finding from 1 review